Repository logo
 

Fate plasticity in the intestine: the devil is in the detail

Published version
Peer-reviewed

Type

Article

Change log

Authors

Abstract

The intestinal epithelium possesses a remarkable ability for both proliferation and regeneration. The last two decades have generated major advances in our understanding of the stem cell populations responsible for its maintenance during homeostasis and more recently the events that occur during injury induced regeneration. These fundamental discoveries have capitalised on the use of transgenic mouse models and in vivo lineage tracing to make their conclusions. It is evident that maintenance is driven by rapidly proliferating crypt base stem cells, but complexities associated with the technicality of mouse modelling have led to several overlapping populations being held responsible for the same behaviour. Similarly, it has been shown that essentially any population in the intestinal crypt can revert to a stem cell state given the correct stimulus during epithelial regeneration. Whilst these observations are profound it is uncertain how relevant they are to human intestinal homeostasis and pathology. Here, these recent studies are presented, in context with technical considerations of the models used, to argue that their conclusions may indeed not be applicable in understanding ‘homeostatic regeneration’ and experimental suggestions presented for validating their results in human tissue.

Description

Keywords

Intestinal stem cell, Lgr5, Plasticity, Regeneration, Animals, Cell Differentiation, Cell Lineage, Cell Proliferation, Disease Models, Animal, Humans, Intestinal Diseases, Intestinal Mucosa, Mice, Models, Animal, Regeneration, Stem Cells

Journal Title

World Journal of Gastroenterology

Conference Name

Journal ISSN

1007-9327
2219-2840

Volume Title

25

Publisher

Baishideng Publishing Group Co. Limited
Sponsorship
Cancer Research UK (A27178)
Medical Research Council (MC_PC_12009)
Supported by a Fellowship grant from Cancer Research UK C14094/A27178; and core funding from Wellcome and MRC to the Wellcome-MRC Cambridge Stem Cell Institute.